极低出生体重儿早期产后高剂量脂溶性肠内维生素A补充对中重度支气管肺发育不良或死亡的影响(NeoVitaA):多中心随机平行组双盲安慰剂对照研究者发起3期试验
NeoVitaA试验在奥地利和德国29个新生儿重症监护病房纳入915例极低出生体重儿,随机接受高剂量肠内维生素A(5000 IU/kg/天)或安慰剂28天,所有患儿均接受基础维生素A补充(1000 IU/kg/天)。
要点
- 极低出生体重儿早期高剂量肠内维生素A补充安全,但未降低中重度支气管肺发育不良或死亡风险。
- 高剂量维生素A未显著提高血清视黄醇浓度,两组不良事件数量相似。
核心结论
- 极低出生体重儿早期产后高剂量脂溶性肠内维生素A补充安全,但未改变中重度支气管肺发育不良或死亡的发生率,也未显著提高血清视黄醇浓度。
研究设计与样本
- 前瞻性、多中心、随机、平行组、双盲、安慰剂对照、研究者发起的3期试验,在奥地利和德国29个新生儿重症监护病房进行。
- 纳入出生体重>400 g且<1000 g、出生孕周≤32+0周、生后72小时内需要机械通气、无创呼吸支持或补充氧气的极低出生体重儿。
- 共筛查3066例婴儿,纳入915例,随机分为高剂量维生素A组(n=449)和对照组(n=466)。
- 高剂量组接受肠内维生素A 5000 IU/kg/天,对照组接受安慰剂(花生油),持续28天;所有参与者均接受基础维生素A补充1000 IU/kg/天。
- 主要复合终点为36周矫正胎龄时中重度支气管肺发育不良或死亡,按意向性治疗人群分析。
主要发现
- 高剂量维生素A组至少发生一次不良事件的参与者为57%(256/449),对照组为60%(281/466),两组相似。
- 基线、干预结束时和36周矫正胎龄时血清视黄醇浓度两组相似。
临床怎么用
- 对于极低出生体重儿,早期产后高剂量肠内维生素A补充(5000 IU/kg/天)未显示可降低中重度支气管肺发育不良或死亡风险,临床决策需结合个体情况。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Vitamin A plays a key role in lung development, but there is no consensus regarding the optimal vitamin A dose and administration route in extremely low birthweight (ELBW) infants. We aimed to assess whether early postnatal additional high-dose fat-soluble enteral vitamin A supplementation versus placebo would lower the rate of moderate or severe bronchopulmonary dysplasia or death in ELBW infants receiving recommended basic enteral vitamin A supplementation. METHODS: This prospective, multicentre, randomised, parallel-group, double-blind, placebo-controlled, investigator-initiated phase 3 trial conducted at 29 neonatal intensive care units in Austria and Germany assessed early high-dose enteral vitamin A supplementation (5000 international units [IU]/kg per day) or placebo (peanut oil) for 28 days in ELBW infants. Eligible infants had a birthweight of more than 400 g and less than 1000 g; gestational age at birth of 32+0 weeks postmenstrual age or younger; and the need for mechanical ventilation, non-invasive respiratory support, or supplemental oxygen within the first 72 h of postnatal age after admission to the neonatal intensive care unit. Participants were randomly assigned by block randomisation with variable block sizes (two and four). All participants received basic vitamin A supplementation (1000 IU/kg per day). The composite primary endpoint was moderate or severe bronchopulmonary dysplasia or death at 36 weeks postmenstrual age, analysed in the intention-to-treat population. This trial was registered with EudraCT, 2013-001998-24. FINDINGS: Between March 2, 2015, and Feb 27, 2022, 3066 infants were screened for eligibility at the participating centres. 915 infants were included and randomly assigned to the high-dose vitamin A group (n=449) or the control group (n=466). Mean gestational age was 26·5 weeks (SD 2·0) and mean birthweight was 765 g (162). Moderate or severe bronchopulmonary dysplasia or death occurred in 171 (38%) of 449 infants in the high-dose vitamin A group versus 178 (38%) of 466 infants in the control group (adjusted odds ratio 0·99, 95% CI 0·73-1·55). The number of participants with at least one adverse event was similar between groups (256 [57%] of 449 in the high-dose vitamin A group and 281 [60%] of 466 in the control group). Serum retinol concentrations at baseline, at the end of intervention, and at 36 weeks postmenstrual age were similar in the two groups. INTERPRETATION: Early postnatal high-dose fat-soluble enteral vitamin A supplementation in ELBW infants was safe, but did not change the rate of moderate or severe bronchopulmonary dysplasia or death and did not substantially increase serum retinol concentrations. FUNDING: Deutsche Forschungsgemeinschaft and European Clinical Research Infrastructures Network (ECRIN).
引用
- Meyer S, Bay J, Franz AR, et al. Early postnatal high-dose fat-soluble enteral vitamin A supplementation for moderate or severe bronchopulmonary dysplasia or death in extremely low birthweight infants (NeoVitaA): a multicentre, randomised, parallel-group, double-blind, placebo-controlled, investigator-initiated phase 3 trial. Lancet Respir Med. 2024. PMID: 38643780. doi:10.1016/S2213-2600(24)00073-0
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。